survival analyses as well as point-prevalence abstinence (34); (d) would be testing the proof of concept AGES using a phenotype (time to first smoking lapse) (TTFSL) not previously reported in extant publications of these four genetic variants using these two clinical trial samples, which reported point-prevalence and continuous abstinence; and (e) was measured during the interval with the highest risk of relapse. Given observations from previously published studies described above, we hypothesized that: (i) individuals with higher AGES scores on bupropion would be less likely to lapse and relapse during treatment and that (ii) individuals with lower scores would be more at risk of relapse on placebo, compared with individuals with lower scores on bupropion, respectively.
